AntriaBio amends $12 million private placement for preferred units

Deal funds clinical trials, research, development, corporate purposes

By Devika Patel

Knoxville, Tenn., Sept. 30 - AntriaBio, Inc. will price a $12 million private placement of preferred units, according to a Form S-1 filed Monday with the Securities and Exchange Commission. The deal was announced as a stock offering on July 1. Ladenburg Thalmann & Co., Inc. is the agent.

The units will consist of one 8% series A convertible preferred and six-year warrants.

Proceeds will be used for clinical trials and efforts to obtain regulatory approval for AB101, developing our other product candidates, research and development and general corporate purposes.

The biopharmaceutical company is based in Menlo Park, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.